Generic Name and Formulations:
Cholera vaccine, live attenuated (V. cholerae strain CVD 103-HgR); 100mL per single dose; susp for oral administration after reconstitution.
Indications for VAXCHORA:
Immunization against disease caused by Vibrio cholerae serogroup 01 in adults 18–64 years of age traveling to cholera-affected areas.
Limitations Of use:
Efficacy not established in persons living in cholera-affected areas or persons with pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. Not shown to protect against disease caused by V. cholerae serogroup 0139 or other non-01 serogroups.
For oral administration only. Avoid food or drink for 60mins before and after administration. ≥18yrs: Give single oral dose a minimum of 10 days before potential cholera exposure.
<18yrs: not established.
Severe allergic reaction to any previous cholera vaccine.
Immunocompromised. Considering whether to administer to individuals with immunocompromised close contacts. Elderly. Pregnancy.
Avoid use within 14 days of systemic antibiotics. Give vaccine ≥10 days prior to antimalarial prophylaxis with chloroquine. Concomitant immunosuppressive therapy (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, high-dose corticosteroids): may get suboptimal response.
Tiredness, headache, abdominal pain, nausea/vomiting, lack of appetite, diarrhea.
To enroll patients in the pregnancy exposure registry call (800) 533-5899.
Single-dose carton—2 packets (buffer component + active component)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC